You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Early Prediction of Fluoxetine Response for Han Chinese Inpatients With Major Depressive Disorder

Lin, Ching-Hua MD*†; Lane, Hsien-Yuan MD, PhD‡§; Chen, Cheng-Chung MD, PhD*; Juo, Suh-Hang Hank MD, PhD∥¶#; Yen, Cheng-Fang MD, PhD**††

Journal of Clinical Psychopharmacology:
doi: 10.1097/JCP.0b013e318210856f
Original Contributions

The onset of antidepressant action is vital clinically. This study aimed to testify whether early symptom improvement can predict eventual treatment response at week 6 among depressive hospitalized patients taking fluoxetine. One hundred thirty-one hospitalized patients with major depressive disorder received 20 mg/d of fluoxetine for 6 weeks. Symptom severity was assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17) at weeks 0, 1, 2, 3, 4, and 6. Stable response was defined as a reduction of 50% or more in the HAMD-17 total score at weeks 4 and 6 of treatment. Receiver operating characteristic curve was used to determine the cutoff point of the percentage of HAMD-17 score reduction between stable responders and nonresponders at weeks 1, 2, 3, and 4. At weeks 1, 2, 3, and 4, HAMD-17 score reductions of 25%, 39%, 43%, and 50% seemed to be the optimal cutoff points for predicting eventual response. They provided a sensitivity of 78%, 86%, 91%, and 93% and a specificity of 61%, 74%, 76%, and 92%. The percentage of HAMD-17 reduction at week 4 excellently predicted final response at week 6. Patients with less than a 50% symptom reduction during the first 4 weeks of treatment are unlikely to reach a final stable response. Whether this model can be applied to establish a prediction system for other antidepressants or for outpatients warrants further research.

Author Information

From the *Kai-Suan Psychiatric Hospital, Kaohsiung; †Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung; ‡Institute of Clinical Medical Science and §Department of Psychiatry, China Medical University Hospital, Taichung; and ∥Department of Medical Research, Kaohsiung Medical University Hospital, ¶Department of Medical Genetics, College of Medicine, #Center of Excellence for Environmental Medicine, **Department of Psychiatry, Faculty of Medicine, College of Medicine, and ††Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Received June 5, 2010; accepted after revision January 14, 2011.

Reprints: Cheng-Fang Yen, MD, PhD, Department of Psychiatry, Kaohsiung Medical University Hospital, 100 Tzyou 1st Rd, Kaohsiung City, Taiwan 807 (e-mail:

This study was funded by the Kai-Suan Psychiatric Hospital in 2007-2009, and National Science Council, Taiwan (NSC-97-2314-B-039-006-MY3 and NSC-98-2627-B-039-001), National Health Research Institutes, Taiwan (NHRI-EX-100-9904NI), Taiwan Department of Health Clinical Trial, and Research Center of Excellence (DOH100-TD-B-111-004).

© 2011 Lippincott Williams & Wilkins, Inc.